Published in Cancer Weekly, April 21st, 2009
"Poly(methyl methacrylate) (PMMA) is a synthetic polymer approved by the Food and Drug Administration for certain human clinical applications such as the bone cement. In vivo, PMMA particles are phagocytosable and have the potential to initiate strong immune responses by stimulating the production of inflammatory cytokines. In this study, we synthesized a series of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2009-04-21)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.